Lilly Can Sue the Sellers. It Can Only Ask the Payment Networks.
- Eli Lilly filed six lawsuits on 12 August 2026 against US entities selling black-market retatrutide, across four federal districts: Aesthetic Envy Cosmetic Centers (N.D. Cal.), Astra Peptides and Texas Peptides (W.D. Tex.), Legendary Peptides (E.D. Tex.), and Striker Pharmacy and Lone Star Peptide (S.D. Tex.). Targets include compounding pharmacies, medical spas and online sellers.
- Retatrutide is an investigational molecule in Phase 3 for obesity, type 2 diabetes and related indications. No medicine containing retatrutide has been approved for human use by any regulatory agency anywhere in the world, and it cannot be sold to consumers.
- Lilly has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards. It has reported more than 14,000 websites, advertisements, social media posts and product listings across over 100 countries to internet service providers, social platforms and e-commerce companies, and states that some continue to amplify the content.
- The suits target sellers claiming their products are for research use only while intending them for human use. The FDA has said sales of unapproved retatrutide to consumers are illegal, that retatrutide cannot be lawfully compounded, and that research-use-only products are of unknown quality. Lilly’s release calls on platforms, credit card companies, payment processors and logistics carriers to cut off the infrastructure.
CI read
The lawsuits are the subhead. The headline is a request addressed to platforms and payment companies. Lilly named its release after the thing it cannot compel, because six suits against small sellers do not touch a market spanning 100 countries.
- Voluntary reporting already failed. Lilly flagged 14,000 listings to platforms and e-commerce companies, then notes some still amplify them. Sellers are replaceable. Payment rails are not.
- The case turns on intent, not labelling. All six suits target research-use-only sellers. That label is what keeps the peptide grey market outside drug regulation. If intent overrides it, the shield goes for every compound.
- The installed base is the exposure. Approved nowhere, selling in 100 countries, filing next year. At launch Lilly inherits patients anchored below its price and adverse events attributed to its molecule.